No Data
Citigroup Starts Acumen Pharmaceuticals With Buy Rating, $7 Price Target
Acumen Pharmaceuticals Price Target Announced at $7.00/Share by Citigroup
Citigroup Initiates Coverage On Acumen Pharmaceuticals With Buy Rating, Announces Price Target of $7
Acumen Pharmaceuticals Analyst Ratings
Citi Initiates Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Announces Target Price $7
Citi analyst David Hoang initiates coverage on $Acumen Pharmaceuticals(ABOS.US)$ with a buy rating, and sets the target price at $7.According to TipRanks data, the analyst has a success rate of 62.8%
Is Acumen Pharmaceuticals (NASDAQ:ABOS) Using Debt In A Risky Way?
No Data